Cargando…

IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma

BACKGROUND: New biomarkers are needed to detect hepatocellular carcinoma at an earlier stage and to individualize treatment strategies. IL-6 has been proven to be associated with liver cancer in numerous studies. AIM: To evaluate the value of the IL-6 promoter methylation level as a noninvasive biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jie-Ru, Wang, Ju, Li, Hai-Ming, Gao, Shuai, Fan, Yu-Chen, Wang, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962649/ https://www.ncbi.nlm.nih.gov/pubmed/35359408 http://dx.doi.org/10.3389/fonc.2022.746643

Ejemplares similares

Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma
por: Liu, Hui-Hui, et al.
Publicado: (2020)

Identifying Apoptosis-Related Transcriptomic Aberrations and Revealing Clinical Relevance as Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma
por: Zhu, Jinyu, et al.
Publicado: (2021)

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Yuan, Shuai, et al.
Publicado: (2020)

Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model
por: Tu, Dao-yuan, et al.
Publicado: (2023)

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
por: Xu, Junnv, et al.
Publicado: (2021)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

IL-10 promoter hypomethylation is associated with increased IL-10 expression and poor survival in hepatocellular carcinoma
por: Zhang, Xianjing, et al.
Publicado: (2019)

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?
por: Upchurch, Garland Michael, et al.
Publicado: (2016)

Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer
por: Ansar, Muhamad, et al.
Publicado: (2022)

DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance
por: Centurione, Lucia, et al.
Publicado: (2016)

IL6 and BCL3 Expression Are Potential Biomarkers in Esophageal Squamous Cell Carcinoma
por: Soares-Lima, Sheila Coelho, et al.
Publicado: (2021)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
por: Zhao, Guangjie, et al.
Publicado: (2021)

Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
por: Yu, Zhenjun, et al.
Publicado: (2021)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

IL10 hypomethylation is associated with the risk of gastric cancer
por: Tang, Junjian, et al.
Publicado: (2021)

F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma
por: Zhang, Ying, et al.
Publicado: (2023)

The Autophagy Related Gene CHAF1B Is a Relevant Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma
por: Zhang, Zunni, et al.
Publicado: (2021)

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets
por: Xu, Jinghang, et al.
Publicado: (2020)

Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma
por: Li, Shuai, et al.
Publicado: (2021)

Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma
por: Li, Tian-Hao, et al.
Publicado: (2021)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis
por: Li, Mei, et al.
Publicado: (2023)

IL-6: The Link Between Inflammation, Immunity and Breast Cancer
por: Chen, Juan, et al.
Publicado: (2022)

Differential Expression Analysis Revealing CLCA1 to Be a Prognostic and Diagnostic Biomarker for Colorectal Cancer
por: Wei, Fang-Ze, et al.
Publicado: (2020)

AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma
por: Ma, Chenxi, et al.
Publicado: (2020)

eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma
por: Zhang, Fangyingnan, et al.
Publicado: (2022)

Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients
por: Liu, Gang, et al.
Publicado: (2022)

Corrigendum: Differential Expression Analysis Revealing CLCA1 to Be a Prognostic and Diagnostic Biomarker for Colorectal Cancer
por: Wei, Fang-Ze, et al.
Publicado: (2020)

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
por: Wang, Ting, et al.
Publicado: (2020)

Cerebrospinal fluid interleukin-6 is a potential diagnostic biomarker for central nervous system involvement in adult acute myeloid leukemia
por: Gu, Jiayan, et al.
Publicado: (2022)

Exploration of a Novel Prognostic Nomogram and Diagnostic Biomarkers Based on the Activity Variations of Hallmark Gene Sets in Hepatocellular Carcinoma
por: Zhong, Xiongdong, et al.
Publicado: (2022)

SP70 is a novel biomarker of hepatocellular carcinoma
por: Wang, Lin, et al.
Publicado: (2023)

Hypomethylation status of miR-657 promoter region as biomarker for diagnosis of hepatocellular carcinoma: a retrospective study
por: Shi, Zhaoqi, et al.
Publicado: (2022)

SMAD3 Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer
por: Ansar, Muhamad, et al.
Publicado: (2020)

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
por: Delmas, Audrey, et al.
Publicado: (2023)

IL-37 Confers Anti-Tumor Activity by Regulation of m6A Methylation
por: Mu, Xiaofeng, et al.
Publicado: (2021)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer
por: Shen, Feifei, et al.
Publicado: (2022)

CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma
por: Karan, Dev
Publicado: (2021)

Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma
por: Song, Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2dslvg358n2bb6ip1tmv1043j2